Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Multi-Center Registry Evaluating Participants Who Receive CanGaroo Envelope or No Envelope During their CIED Implantation
This prospective, multi-center study will enroll up to 500 participants who are undergoing their initial CIED implant with either a CanGaroo envelope or no envelope.
Once a participant is enrolled in one of the two cohorts, each participant will have their medical history data reviewed and data will be recorded in the CRF including baseline demographics, medications, and diagnoses.
The details of the CIED procedure including any complications/AEs that occur during the procedure will be captured on the appropriate CRF.
Information collected at the follow-up visits will include documentation of post-procedure status, including any complications, adverse events, or revision/reoperation procedures that occur during the follow-up period. This information will also be collected for any unscheduled follow-ups, visits, or care encounters that occur up to 3 months post-procedure. For participants that agree and qualify for optional long-term follow-up, the same information will be collected at additional follow-up points every six months for up to five years.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CanGaroo Envelope | Participants who receive a CanGaroo envelope during their CIED implant. |
| |
| No Envelope | Participants who do not receive an envelope of any kind during their CIED implant. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CanGaroo Envelope | Device | Utilization of a CanGaroo envelope with the CIED during the participant's CIED implant procedure. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Association between participant characteristics and outcomes | Cohort comparison of clinically significant factors such as physical and demographic characteristics, medical history risk factors related to post-procedure events, and associations with outcomes and events. | 3 months post-procedure |
| Association between CanGaroo envelope use and CIED implant-related outcomes and events. | Cohort comparison of clinically significant events such as infection, wound healing issues, CIED migration, CIED erosion, or a revision/reoperation procedure. | 3 months post-procedure |
Not provided
Not provided
Inclusion Criteria:
Participants for whom this is their first CIED implantation at a particular anatomical site.
Participants with a history of prior CIED implants at other anatomical sites than the current site can be included, provided that the planned implant location for the current CIED procedure is the first implant procedure at that site.
Participants aged 18 years or older at time of enrollment.
Participant is able and agrees to provide written informed consent and use of PHI.
Exclusion Criteria:
Not provided
Not provided
Not provided
Up to 500 participants who will either receive a CanGaroo envelope or no envelope during their de novo cardiac implantable electronic device implantation.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Thomas F. Deering, MD | Piedmont Heart Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Arkansas Heart Hospital | Little Rock | Arkansas | 72211 | United States | ||
| Daytona Heart Group |
Not provided
| Label | URL |
|---|---|
| Aziyo Biologics, Inc. website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Daytona Beach |
| Florida |
| 32114 |
| United States |
| The Arrhythmia Center of South Florida | Delray Beach | Florida | 33484 | United States |
| Florida Heart Rhythm Specialists, PLLC | Fort Lauderdale | Florida | 33308 | United States |
| VA Medical Center | Gainesville | Florida | 32607 | United States |
| Cardiovascular Associates/Osceola Regional Medical Center | Kissimmee | Florida | 34741 | United States |
| Advent Health | Tampa | Florida | 33613 | United States |
| Baptist Health Floyd | New Albany | Indiana | 47150 | United States |
| St. Joseph Hospital | Lexington | Kentucky | 40504 | United States |
| Eastern Maine Medical Center | Bangor | Maine | 04401 | United States |
| Brigham & Women's Hospital, Cardiovascular Division | Boston | Massachusetts | 02115 | United States |
| Sparrow Clinical Research Institute | Lansing | Michigan | 48912 | United States |
| Ascension Providence Hospital | Southfield | Michigan | 48075 | United States |
| Metro Health/University of Michigan Health | Wyoming | Michigan | 49519 | United States |
| UNC Health/NC Heart & Vascular Research | Raleigh | North Carolina | 27607 | United States |
| New Hanover Regional Medical Center | Wilmington | North Carolina | 28401 | United States |
| Mercy Health | Toledo | Ohio | 43608 | United States |
| Oklahoma State University Center for Health Sciences | Tulsa | Oklahoma | 74127 | United States |
| University of Pennsylvania Hospital | Philadelphia | Pennsylvania | 19104 | United States |
| Carolina Heart Specialists | Lancaster | South Carolina | 29720 | United States |
| University of Texas Medical Branch | Galveston | Texas | 77555 | United States |
| Houston Methodist | Houston | Texas | 77030 | United States |
| Heart Rhythm Associates | The Woodlands | Texas | 77380 | United States |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided